{"Clinical Trial ID": "NCT00454805", "Intervention": ["INTERVENTION 1:", "Cediranib 45 mg", "Cediranib 45 mg+Fulvestant 250 mg", "Patients randomised to the experimental arm (fluvestrant + cediranib) were treated according to the following regimen:", "Day 1: flauvestrant 500 mg", "Day 15: flulvestant 250 mg im", "Day 29, then every 28 days: smoking 250 mg daily", "(Administered orally)", "INTERVENTION 2:", "- Placebo", "Placebo+Fulvestant 250 mg", "Patients randomised to the control arm (fluvestrant + placebo) were treated according to the following regimen:", "Day 1: flauvestrant 500 mg", "Day 15: flulvestant 250 mg im", "Day 29, then every 28 days: smoking 250 mg daily", "One placebo corresponding to cediranib (administered orally)"], "Eligibility": ["Incorporation criteria:", "Written consent with knowledge of the case", "Women with histological/cytological confirmation of hormone-sensitive breast cancer with signs of metastatic disease", "One or more evaluable lesions", "- Exclusion criteria:", "\u2022 Prior hormonal treatment with fluvestrant", "More than one previous cycle of systemic cytotoxic chemotherapy for metastatic breast cancer", "\u2022 Prior biological treatment for ABC including anti-VEGF agents", "Radiotherapy within 4 weeks prior to consent"], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "Number of months from randomization to a progressive disease based on RECIST (progress of target lesions, clear progression of existing non-target lesions or occurrence of one or more new lesions) or death in the absence of progression.", "Time limit: RECIST performed at screening and every 8 weeks until progression or discontinuation, as soon as possible.", "Results 1:", "Title of the arm/group: Cediranib 45 mg", "Description of the arm/group: Cediranib 45 mg+Fulvestant 250 mg", "Patients randomised to the experimental arm (fluvestrant + cediranib) were treated according to the following regimen:", "Day 1: flauvestrant 500 mg", "Day 15: flulvestant 250 mg im", "Day 29, then every 28 days: smoking 250 mg daily", "(Administered orally)", "Total number of participants analysed: 31", "Median (95% confidence interval)", "Unit of measure: days 223 (129 to 340)", "Results 2:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo+Fulvestant 250 mg", "Patients randomised to the control arm (fluvestrant + placebo) were treated according to the following regimen:", "Day 1: flauvestrant 500 mg", "Day 15: flulvestant 250 mg im", "Day 29, then every 28 days: smoking 250 mg daily", "One placebo corresponding to cediranib (administered orally)", "Total number of participants analysed: 31", "Median (95% confidence interval)", "Unit of measurement: days 112 (59-329)"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/31 (48.39 per cent)", "1/31 (3.23%)", "Diarrhoea 2/31 (6.45%)", "Nausea 2/31 (6.45 per cent)", "Vomiting 2/31 (6.45 per cent)", "Ascites 0/31 (0.00 %)", "Ileus 1/31 (3.23%)", "Small intestinal obstruction 1/31 (3.23%)", "- Multi-organism failure 0/31 (0.00 %)", "\u2022 Sepsis 1/31 (3.23%)", "Decrease in weight 1/31 (3.23%)", "Dehydration 2/31 (6.45%)", "Hypokalaemia 0/31 (0.00 %)", "Adverse Events 2:", "Total: 4/31 (12.90 per cent)", "- Intracardiac thrombus 0/31 (0.00 %)", "Diarrhoea 0/31 (0.00 %)", "Nausea 0/31 (0.00 %)", "Vomiting 0/31 (0.00 %)", "Ascites 1/31 (3.23%)", "Ileus 0/31 (0.00 %)", "Small intestinal obstruction 0/31 (0.00 %)", "1/31 (3.23%)", "- Sepsis 0/31 (0.00 %)", "Decrease in weight 0/31 (0.00 %)", "Dehydration 0/31 (0.00 %)", "Hypokalaemia 1/31 (3.23%)"]}